9 recruiting, 1 active not recruiting, 1 completed, 1 terminated. 10 Phase 2, 2 Early Phase 1, 2 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 7, Completed 1, Unknown 1, Withdrawn 1 |
| Early Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Not applicable | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow this condition Literature Review of Hypopharyngeal Squamous Cell Carcinoma trials Research Report on Hypopharyngeal Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma Becotatug Vedotin and Pucotenlimab - Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 52 | 2026-07-01 | 2026-07-16 |
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 44 | 2026-05-27 | 2026-10-16 |
| Window of Opportunity in Preserving Laryngeal Function Trial Toripalimab, Carboplatin, Cisplatin - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | Matthew Spector | 87 | 2026-04-06 | 2026-10-16 |
| Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer Compartmentalized Postoperative Radiotherapy - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Olgun Elicin | 50 | 2026-01-15 | 2026-08-27 |
| Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation Audiometric Test, Interview - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck | Not applicable | Recruiting | Emory University | 118 | 2025-08-25 | 2026-07-16 |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer Best Practice, Biospecimen Collection, Cisplatin - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | NRG Oncology | 98 | 2025-06-23 | 2026-08-17 |
| Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer Computed Tomography, Fludeoxyglucose F-18, Intensity-Modulated Proton Therapy - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Early Phase 1 | Recruiting | Emory University | 20 | 2024-12-03 | 2025-10-22 |
| European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] KEYTRUDA® - Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | University of Leipzig | 140 | 2024-04-17 | 2024-09-20 |
| Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer Biospecimen Collection, Carboplatin, Chest Radiography - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Withdrawn | ECOG-ACRIN Cancer Research Group | 2024-04-12 | 2024-07-25 | |
| Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal Cancer induction chemotherapy, surgery, chemoradiotherapy - Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Unknown | Peking Union Medical College Hospital | 100 | 2020-03-01 | 2020-03-05 |
| Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Cetuximab, Durvalumab, Intensity-Modulated Radiation Therapy - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 196 | 2018-04-03 | 2026-08-27 |
| Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma Intensity-Modulated Radiation Therapy (IMRT), Trans Oral Surgery (TOS) - Oropharyngeal Cancer, Supraglottic Squamous Cell Carcinoma | Not applicable | Active not recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 112 | 2017-11-27 | 2025-08-14 |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | ECOG-ACRIN Cancer Research Group | 189 | 2016-11-23 | 2026-09-14 |
| Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Bupropion Hydrochloride, Laboratory Biomarker Analysis, Nicotine Replacement - Current Smoker, Head and Neck Squamous Cell Carcinoma | Early Phase 1 | Terminated | Wake Forest University Health Sciences | 9 | 2016-01-01 | 2023-03-22 |
Squamous Cell Carcinoma of Head and Neck (14) · Laryngeal Neoplasms (8) · Carcinoma (7) · Hypopharyngeal Neoplasms (7) · Mouth Neoplasms (6) · Oropharyngeal Neoplasms (5) · Nasopharyngeal Carcinoma (4) · Head and Neck Neoplasms (1) · Lymphoid Interstitial Pneumonia (1) · Neoplasm Metastasis (1) · Recurrence (1) · Stomatitis (1)
Carcinoma, Squamous Cell (14) · Neoplasms (14) · Neoplasms by Histologic Type (14) · Neoplasms by Site (14) · Neoplasms, Glandular and Epithelial (14) · Head and Neck Neoplasms (13) · Otorhinolaryngologic Diseases (11) · Otorhinolaryngologic Neoplasms (11) · Pharyngeal Diseases (10) · Pharyngeal Neoplasms (10) · Stomatognathic Diseases (10) · Laryngeal Diseases (8) · Respiratory Tract Diseases (8) · Respiratory Tract Neoplasms (8) · Carcinoma (7)
Radiotherapy, Intensity-Modulated (7) · Cisplatin (4) · Magnetic Resonance Spectroscopy (4) · 1,2-diaminocyclohexaneplatinum II citrate (3) · Platinum (3) · Specimen Handling (3) · Carboplatin (2) · Radiotherapy, Image-Guided (2) · (225)Ac-DOTA-c(RGDyK) (1) · Albumin-Bound Paclitaxel (1) · Biopsy (1) · Bupropion (1) · Cetuximab (1) · Chemoradiotherapy (1) · Disulfides (1)
ECOG-ACRIN Cancer Research Group (2) · Emory University (2) · National Cancer Institute (NCI) (2) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Matthew Spector (1) · NRG Oncology (1) · Olgun Elicin (1) · Peking Union Medical College Hospital (1) · Tianjin Medical University Cancer Institute and Hospital (1) · University of Leipzig (1) · Wake Forest University Health Sciences (1)
United States (8) · Germany (2) · Switzerland (2) · Belgium (1) · Canada (1) · China (1) · France (1) · Italy (1) · Poland (1) · Spain (1) · United Kingdom (1)
Amol M Takalkar, MD, MS, MBA, FACNM (1) · Christian Simon (1) · Chunmei Bai (1) · David M Brizel (1) · Heath D Skinner (1) · Loren K Mell (1) · Matin Imanguli (1) · Matthew Spector, MD, FACS (1) · Mercedes Porosnicu (1) · Nicole C Schmitt, MD, FACS (1) · Robert Ferris (1) · Timo Nannen (1)
PMID 33605440, PMID 39239277, PMID 39551064
P30CA138292 (2), U10CA180820 (2), K24DC022077 (1), P30CA012197 (1), U10CA180868 (1), UG1CA189867 (1), UM1CA186691 (1)